Geode Capital Management, LLC Xencor Inc Transaction History

Geode Capital Management, LLC

  • $1.12 Trillion
  • Q2 2024

A detailed history of Geode Capital Management, LLC transactions in Xencor Inc stock. As of the latest transaction made, Geode Capital Management, LLC holds 1,437,692 shares of XNCR stock, worth $33.3 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
1,437,692
Previous 1,349,786 6.51%
Holding current value
$33.3 Million
Previous $29.9 Million 8.89%
% of portfolio
0.0%
Previous 0.0%

Shares

29 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 09, 2024
BUY
$18.21 - $24.5 $1.6 Million - $2.15 Million
87,906 Added 6.51%
1,437,692 $27.2 Million
Q1 2024

May 13, 2024
BUY
$18.65 - $26.52 $649,821 - $924,036
34,843 Added 2.65%
1,349,786 $29.9 Million
Q4 2023

Feb 13, 2024
BUY
$16.53 - $21.42 $909,001 - $1.18 Million
54,991 Added 4.36%
1,314,943 $27.9 Million
Q3 2023

Nov 13, 2023
BUY
$20.08 - $25.39 $993,176 - $1.26 Million
49,461 Added 4.09%
1,259,952 $25.4 Million
Q2 2023

Aug 11, 2023
BUY
$24.77 - $29.9 $1.26 Million - $1.52 Million
50,808 Added 4.38%
1,210,491 $30.2 Million
Q1 2023

May 15, 2023
BUY
$25.95 - $36.95 $758,985 - $1.08 Million
29,248 Added 2.59%
1,159,683 $32.3 Million
Q4 2022

Feb 13, 2023
BUY
$24.79 - $30.86 $1.24 Million - $1.54 Million
49,947 Added 4.62%
1,130,435 $29.4 Million
Q3 2022

Nov 14, 2022
BUY
$24.62 - $32.44 $322,374 - $424,769
13,094 Added 1.23%
1,080,488 $28.1 Million
Q2 2022

Aug 12, 2022
BUY
$19.74 - $29.01 $702,309 - $1.03 Million
35,578 Added 3.45%
1,067,394 $29.2 Million
Q1 2022

May 13, 2022
BUY
$26.68 - $41.63 $624,818 - $974,932
23,419 Added 2.32%
1,031,816 $27.5 Million
Q4 2021

Feb 11, 2022
SELL
$33.67 - $43.44 $525,150 - $677,533
-15,597 Reduced 1.52%
1,008,397 $40.5 Million
Q3 2021

Nov 12, 2021
BUY
$30.65 - $35.68 $752,059 - $875,480
24,537 Added 2.46%
1,023,994 $33.4 Million
Q2 2021

Aug 13, 2021
BUY
$34.33 - $44.68 $1.61 Million - $2.1 Million
46,980 Added 4.93%
999,457 $34.5 Million
Q1 2021

May 12, 2021
BUY
$40.81 - $53.88 $2.4 Million - $3.18 Million
58,930 Added 6.6%
952,477 $41 Million
Q4 2020

Feb 12, 2021
BUY
$36.63 - $47.63 $2.36 Million - $3.06 Million
64,335 Added 7.76%
893,547 $39 Million
Q3 2020

Nov 13, 2020
BUY
$30.09 - $43.02 $701,849 - $1 Million
23,325 Added 2.89%
829,212 $32.2 Million
Q2 2020

Aug 13, 2020
BUY
$27.76 - $33.42 $2.06 Million - $2.48 Million
74,322 Added 10.16%
805,887 $26.1 Million
Q1 2020

May 14, 2020
BUY
$20.69 - $37.79 $878,621 - $1.6 Million
42,466 Added 6.16%
731,565 $21.9 Million
Q4 2019

Feb 13, 2020
BUY
$32.75 - $41.43 $1.17 Million - $1.48 Million
35,801 Added 5.48%
689,099 $23.7 Million
Q3 2019

Nov 12, 2019
BUY
$33.73 - $46.27 $525,985 - $721,534
15,594 Added 2.45%
653,298 $22 Million
Q2 2019

Aug 14, 2019
BUY
$29.6 - $40.93 $1.22 Million - $1.69 Million
41,305 Added 6.93%
637,704 $26.1 Million
Q1 2019

May 14, 2019
BUY
$27.85 - $38.09 $1.27 Million - $1.74 Million
45,757 Added 8.31%
596,399 $18.5 Million
Q4 2018

Feb 13, 2019
BUY
$32.39 - $42.05 $1.23 Million - $1.6 Million
38,127 Added 7.44%
550,642 $19.9 Million
Q3 2018

Nov 13, 2018
BUY
$35.69 - $47.65 $726,933 - $970,535
20,368 Added 4.14%
512,515 $20 Million
Q2 2018

Aug 14, 2018
BUY
$28.41 - $42.41 $2.82 Million - $4.2 Million
99,099 Added 25.21%
492,147 $18.2 Million
Q1 2018

May 15, 2018
BUY
$21.18 - $33.78 $858,255 - $1.37 Million
40,522 Added 11.49%
393,048 $11.8 Million
Q4 2017

Feb 13, 2018
BUY
$19.29 - $24.83 $380,128 - $489,299
19,706 Added 5.92%
352,526 $7.73 Million
Q3 2017

Nov 14, 2017
SELL
$19.61 - $23.35 $877,312 - $1.04 Million
-44,738 Reduced 11.85%
332,820 $7.63 Million
Q2 2017

Aug 14, 2017
BUY
N/A
377,558
377,558 $7.97 Million

Others Institutions Holding XNCR

# of Institutions
200
Shares Held
63.2M
Call Options Held
3.9K
Put Options Held
3K
View Full List

About Xencor Inc

XNCR Quotes by TradingView
  • Ticker XNCR
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,698,100
  • Market Cap $1.38B
  • Description
  • Xencor, Inc., a clinical stage biopharmaceutical company, focuses on the discovery and development of engineered monoclonal antibody and cytokine therapeutics to treat patients with cancer and autoimmune diseases. The company provides Sotrovimab that targets the SARS-CoV-2 virus; Ultomiris for the treatment of patients with paroxysmal nocturnal ...
More about XNCR
Track This Portfolio

Track Geode Capital Management, LLC Portfolio

Follow Geode Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Geode Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Geode Capital Management, LLC with notifications on news.

Choose your preferred platform and Sign Up 👇 Telegram Email